 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for CRYAA |
 Gene summary |
| Basic gene information | Gene symbol | CRYAA |
| Gene name | crystallin, alpha A | |
| Synonyms | CRYA1|CTRCT9|HSPB4 | |
| Cytomap | UCSC genome browser: 21q22.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000394.3, | |
| Description | alpha-crystallin A chaincrystallin, alpha-1heat shock protein beta-4human alphaA-crystallin (CRYA1) | |
| Modification date | 20141218 | |
| dbXrefs | MIM : 123580 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000160202 | ||
| HPRD : 00427 | ||
| Vega : OTTHUMG00000086842 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CRYAA | |
| BioGPS: 1409 | ||
| Pathway | NCI Pathway Interaction Database: CRYAA | |
| KEGG: CRYAA | ||
| REACTOME: CRYAA | ||
| Pathway Commons: CRYAA | ||
| Context | iHOP: CRYAA | |
| ligand binding site mutation search in PubMed: CRYAA | ||
| UCL Cancer Institute: CRYAA | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | KidneyEye | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | KIRC,KIRP,KICHUVM | |
| Reference showing the relevant tissue of CRYAA | Identification of differentially expressed proteins in retinoblastoma tumors using mass spectrometry-based comparative proteomic approach. Naru J, Aggarwal R, Mohanty AK, Singh U, Bansal D, Kakkar N, Agnihotri N. J Proteomics. 2017 Apr 21;159:77-91. doi: 10.1016/j.jprot.2017.02.006. Epub 2017 Feb 13 (pmid:28232133) go to article | |
| Description by TissGene annotations | Risk TissGene in RFS Cancer gene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0032387 | negative regulation of intracellular transport | 14752512 | GO:0043066 | negative regulation of apoptotic process | 14752512 | GO:0051260 | protein homooligomerization | 16303126 | GO:0032387 | negative regulation of intracellular transport | 14752512 | GO:0043066 | negative regulation of apoptotic process | 14752512 | GO:0051260 | protein homooligomerization | 16303126 |
| Top |
| TissGeneExp for CRYAA |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LIHC | 3.745672323 | 6.168748323 | -2.423076 | 2.58E-05 | 9.95E-05 |
| KIRC | -0.046084844 | 4.574113768 | -4.620198611 | 1.92E-13 | 8.64E-13 |
| KICH | -2.028119677 | 4.431456323 | -6.459576 | 1.08E-09 | 6.71E-09 |
| KIRP | -0.501377552 | 6.189578698 | -6.69095625 | 6.50E-13 | 1.08E-11 |
| Top |
| TissGene-miRNA for CRYAA |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for CRYAA |
| TissGeneSNV for CRYAA |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.S132F | SKCM | 2 |
| p.G30S | SKCM | 1 |
| p.D136Y | BLCA | 1 |
| p.R103H | SARC | 1 |
| p.G98R | SKCM | 1 |
| p.R12H | HNSC | 1 |
| p.S41L | SKCM | 1 |
| p.V161M | UCEC | 1 |
| p.S51F | LUAD | 1 |
| p.D24N | PRAD | 1 |
| p.R54C | LUSC | 1 |
| p.P160L | SKCM | 1 |
| p.P46S | SKCM | 1 |
| p.L139M | UCEC | 1 |
| p.R49H | KIRC | 1 |
| p.R163W | LGG | 1 |
| p.E33K | LIHC | 1 |
| p.P8S | SKCM | 1 |
| p.Y109N | SKCM | 1 |
| Top |
| TissGeneCNV for CRYAA |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for CRYAA |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for CRYAA |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (tumor) | CRYAA, BCL2L1, ALB, CRYZ, CRYAB, HSPB1, CS, LALBA, CRYBB2, CRYGC, MIP (normal) |
 |  |
| Top |
| TissGeneProg for CRYAA |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for CRYAA |
| TissGeneDrug for CRYAA |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for CRYAA |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0086543 | Cataract | 23 | BeFree,CTD_human,GAD,LHGDN,RGD |
| umls:C0521707 | Bilateral cataracts (disorder) | 7 | BeFree |
| umls:C0009691 | Congenital cataract | 6 | BeFree |
| umls:C1858679 | CATARACT, AUTOSOMAL DOMINANT | 5 | CLINVAR,MGD,UNIPROT |
| umls:C0392557 | Nuclear cataract | 3 | BeFree,ORPHANET |
| umls:C1112705 | Nuclear non-senile cataract | 3 | BeFree,ORPHANET |
| umls:C0036646 | Age-related cataract | 2 | BeFree,GWASCAT |
| umls:C0042164 | Uveitis | 2 | CTD_human |
| umls:C0266544 | Microcornea | 2 | BeFree |
| umls:C0001857 | AIDS related complex | 1 | BeFree |
| umls:C0004364 | Autoimmune Diseases | 1 | CTD_human |
| umls:C0009363 | Congenital ocular coloboma (disorder) | 1 | LHGDN |
| umls:C0010038 | Corneal Opacity | 1 | LHGDN |
| umls:C0016952 | Galactosemias | 1 | RGD |
| umls:C0028840 | Ocular Hypertension | 1 | RGD |
| umls:C0240063 | Coloboma of iris | 1 | BeFree |
| umls:C0266551 | Congenital coloboma of iris | 1 | BeFree |
| umls:C1510497 | Lens Opacities | 1 | BeFree |
| umls:C1832423 | Cataract, Age-Related Nuclear | 1 | BeFree |
| umls:C1861821 | CATARACT, MARNER TYPE | 1 | BeFree |
| umls:C0266539 | Congenital total cataract | 0 | ORPHANET |
| umls:C1855179 | CATARACT, ANTERIOR POLAR | 0 | ORPHANET |
| umls:C1861829 | Cataract microcornea syndrome | 0 | ORPHANET |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |